The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Apr. 15, 2013
Applicant:

Baylor Research Institute, Dallas, TX (US);

Inventors:

Jacques F. Banchereau, Dallas, TX (US);

Gerard Zurawski, Midlothian, TX (US);

Sandra Zurawski, Midlothian, TX (US);

Eynav Klechevsky, Haifa, IL;

SangKon Oh, Baltimore, MD (US);

Assignee:

Baylor Research Institute, Dallas, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01); A61K 39/21 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 39/12 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/21 (2013.01); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 16/2851 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/6056 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01); C12N 2740/16034 (2013.01); C12N 2760/16134 (2013.01);
Abstract

The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.


Find Patent Forward Citations

Loading…